DDD

Zeitview Reveals 51% of Large-Scale U.S. Solar Plants are in 'Excellent' or 'Good' Condition

Retrieved on: 
Thursday, September 7, 2023
Software, Alternative Energy, Energy, Artificial Intelligence, Data Management, Technology, Aerospace, Manufacturing, GW, Intelligence, Multimedia, Temperature, PV, Plant, BBB, Acquisition, AAA, DDD, Heel, O&M, Maintenance (technical), Health, Letter, News, Renewable energy, Maintenance

View the full release here: https://www.businesswire.com/news/home/20230907696936/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230907696936/en/
    Using crewed aircraft to capture aerial imagery and thermal scans, Zeitview successfully recorded data on 95 GW of the United States fleet of solar power plants during the 2023 North American Solar Scan.
  • On average, larger plants tend to be healthy, with more than 50% of the 100 MW and larger fleets in excellent or good condition.
  • Using crewed aircraft to capture aerial imagery and thermal scans, Zeitview successfully recorded asset condition data on 95 GW of the United States fleet of solar power plants during the 2023 North American Solar Scan.
  • Zeitview applies a three-letter asset rating system from AAA to DDD upon scan completion to reflect a site's condition.

Nano Dimension Sends Letter to Shareholders

Retrieved on: 
Tuesday, August 8, 2023
FOR, NANO, American depositary receipt, NO, Annual general meeting, Metal, J. James Exon, DM, Integration, 3D, LTM, NUALS Arts and Literary Annual Meet, Growth, Security (finance), ALL, Form 10-K, Disclosure, Security Commission, History, 3D Systems, 3D printing, Letter, Ontario Securities Commission, F-36, Bring Your Board!!, VLD, DDD, AI, Robotics, Annual report, OSC, Auction, Management, Video game, Risk management, Mobile phone, Online shopping, Holding company

Waltham, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension”, “Nano” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”) 3D printers, today sent a letter to shareholders in connection with the Company’s upcoming 2023 Annual General Meeting of Shareholders (“the Annual Meeting”). The letter highlights the strength of the directors on Nano’s Board of Directors (the “Board”), all of whom are highly qualified and critical to the Company’s success and ability to continue driving long-term value for all shareholders. The letter also underscores Murchinson’s self-interested campaign to elevate its profile and gain access to the Company’s significant cash reserves at the expense of other shareholders.

Key Points: 
  • Murchinson’s Self-Serving Campaign is a Blatant Attempt to Obtain Nano’s Cash Reserves Without Paying Full Value to Shareholders, While Elevating its Profile as an “Activist”
    Waltham, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension”, “Nano” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”) 3D printers, today sent a letter to shareholders in connection with the Company’s upcoming 2023 Annual General Meeting of Shareholders (“the Annual Meeting”).
  • The letter also underscores Murchinson’s self-interested campaign to elevate its profile and gain access to the Company’s significant cash reserves at the expense of other shareholders.
  • At the upcoming Annual General Meeting (“AGM”) of Shareholders on Thursday, September 7, 2023, you have an important decision to make regarding the future of your investment in Nano Dimension Ltd. (“Nano Dimension”, the “Company” or “Nano”):
    Protect the long-term value creation opportunity your Nano Dimension shares present by voting FOR all 9 of the Company’s board nominees, or
    Allow a self-interested bad actor to gain access to liquidate your company to access the significant cash reserves for their own benefit.
  • Overall, companies acquired by Nano have significantly outgrown and outpaced peers in the industry after joining Nano.

Top Commercial Payer in Michigan Significantly Expands Patient Access to Centinel Spine's prodisc® L for One- and Two-level Lumbar Total Disc Replacement

Retrieved on: 
Wednesday, July 26, 2023
WEST, Policy, Quality of life, Outline, Publication, Patient, Samuel Bryan, DDD, TDR, Health insurance

The largest commercial payer in Michigan, representing 5.8 million covered lives, has established positive coverage effective September 1 2023 for both one- and two-level lumbar total disc replacement (LTDR) procedures, which includes prodisc®L.

Key Points: 
  • The largest commercial payer in Michigan, representing 5.8 million covered lives, has established positive coverage effective September 1 2023 for both one- and two-level lumbar total disc replacement (LTDR) procedures, which includes prodisc®L.
  • This major positive coverage update continues the trend for one-level lumbar TDR over the last several years, moving the number of covered lives from under 50% in 2017 to now approaching universal coverage for commercial payers.
  • The commercial payer, the largest operating payer in Michigan, previously had no coverage policy for either one- or two-level lumbar TDR.
  • The new positive coverage policy opens access to patients suffering from symptomatic degenerative disc disease (DDD) who can benefit from lumbar TDR using prodisc L for both one- and two-level lumbar TDR.

Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial

Retrieved on: 
Thursday, July 13, 2023
Spinal fusion, CT, Surgeon, Brigham and Women's Hospital, Degenerative disc disease, UCSD, PTH, Kuros, Investigational New Drug, Patient, DDD, PLF, Hospital, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry, Medical imaging

Fibrin-PTH is a novel parathyroid hormone-based healing matrix allowing targeted, controlled bone generation.

Key Points: 
  • Fibrin-PTH is a novel parathyroid hormone-based healing matrix allowing targeted, controlled bone generation.
  • Fibrin-PTH targets a substantial clinical need and, upon approval, will address the large musculoskeletal growth factor market projected to reach $2.2B by 2030.
  • The primary endpoint of the trial is radiographic interbody fusion using CT scans at 12 months, as determined by an independent radiology expert panel.
  • Upon successful completion of the Phase 2 study, the Phase 3 program will be initiated.

Queclink at MWC Shanghai 2023: Bringing Tomorrow's IoT Solutions to Today's Markets

Retrieved on: 
Wednesday, June 28, 2023
Exhibition, GNSS, Internet of things, Multimedia, DDD, Growth, SC300, Ecosystem, Transport, LTE, Satellite navigation device, Mobile phone, Mobile World Congress

SHANGHAI, June 28, 2023 /PRNewswire/ -- Queclink, a global provider of IoT devices and solutions, recently participated in this year's MWC Shanghai, where it showcased its latest IoT devices and solutions.

Key Points: 
  • SHANGHAI, June 28, 2023 /PRNewswire/ -- Queclink, a global provider of IoT devices and solutions, recently participated in this year's MWC Shanghai, where it showcased its latest IoT devices and solutions.
  • MWC Shanghai is the largest and most influential gathering of the connectivity ecosystem in Asia.
  • At the event, Queclink featured various IoT devices and solutions, such as GNSS trackers, video telematics solutions, e-mobility devices, industrial routers, and animal ear tags, catering to the needs of various vertical markets, businesses, and alike.
  • With its 5G industrial router and animal ear tags, Queclink's showcased solutions also reached beyond transportation and logistics markets and into varying applications.

BCWorld Healthcare and ReGelTec have entered into an exclusive distribution agreement for HYDRAFIL™ in the South Korean market

Retrieved on: 
Thursday, June 1, 2023
Pharmaceutical, Health, Other Health, Medical Devices, Partnership, Ministry of Food and Drug Safety, Tears, FDA Center for Devices and Radiological Health, MFDS, Trial of the century, Ministry, Degenerative disc disease, Patient, DDD, Pain management, Device, FDA, Safety, Pharmaceutical industry, Food

ReGelTec, Inc. (ReGelTec) announced that it has entered into an agreement with BCWorld Healthcare Co., Ltd. (BCWH) that provides BCWP exclusive rights to distribute the HYDRAFIL™ System for the treatment of Chronic Low Back Pain (CLBP) due to Degenerative Disc Disease (DDD) in the South Korean market.

Key Points: 
  • ReGelTec, Inc. (ReGelTec) announced that it has entered into an agreement with BCWorld Healthcare Co., Ltd. (BCWH) that provides BCWP exclusive rights to distribute the HYDRAFIL™ System for the treatment of Chronic Low Back Pain (CLBP) due to Degenerative Disc Disease (DDD) in the South Korean market.
  • BCWH will also fund a clinical study in South Korea to support regulatory approval from the Ministry of Food and Drug Safety (MFDS) with ReGelTec providing HYDRAFIL™ Systems for the study.
  • The companies have already started planning regulatory strategies for approval and expect the trial to begin in 2024.
  • “We are excited to secure the rights to distribute the HYDRAFIL™ System in South Korea,” said Steve Hong, CEO and President of BCWH.

Locate Bio’s LDGraft Granted FDA Breakthrough Device Designation

Retrieved on: 
Thursday, May 18, 2023
Medical Devices, FDA, Health, Surgery, Pharmaceutical, Biotechnology, Spinal fusion, Surgeon, Low back pain, Bio, Degenerative disc disease, Disability, Myelopathy, Quality of life, Bone morphogenetic protein 2, Spinal disc herniation, Radiculopathy, Patient, DDD, Diagnosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Spinal stenosis, Pharmaceutical industry, Locate

Locate Bio, a UK-based orthobiologics company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for LDGraft, currently in development for anterior lumbar interbody spinal fusion (ALIF) procedures at one level from L3-S1 for patients with degenerative disc disease.

Key Points: 
  • Locate Bio, a UK-based orthobiologics company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for LDGraft, currently in development for anterior lumbar interbody spinal fusion (ALIF) procedures at one level from L3-S1 for patients with degenerative disc disease.
  • The FDA Breakthrough Device Program is designed to accelerate patient access to promising technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.
  • We are delighted therefore to have been granted a Breakthrough Device designation from the FDA for LDGraft, our exciting controlled and extended-release rhBMP-2 for spinal fusion.
  • We are proud that the FDA has recognised the potential of LDGraft.

VySpine Announces FDA Clearance for UniVy OsteoVy-Ti Cervical IBF with NanoVy-HA

Retrieved on: 
Tuesday, April 25, 2023
FDA, Health, Surgery, Medical Devices, 3D, Partnership, Regeneration, Spine, Degenerative disc disease, DDD, United States v. Univis Lens Co., Ceramic

The UniVy OsteoVy-Ti NanoVy-HA Cervical IBF System features VySpine's NanoVy-HA technology in partnership with Promimic AB.

Key Points: 
  • The UniVy OsteoVy-Ti NanoVy-HA Cervical IBF System features VySpine's NanoVy-HA technology in partnership with Promimic AB.
  • NanoVy-HA is a process in which the 3D printed UniVy OsteoVy-Ti implant is surface-treated with hydroxyapatite.
  • The NanoVy-HA technology is engineered to facilitate enhanced bone integration and quality to the entire surface of the UniVy OsteoVy-Ti implant.
  • The UniVy OsteoVy-Ti NanoVy-HA Cervical IBF System features optimal pore size and structure.

Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia

Retrieved on: 
Tuesday, April 11, 2023
Research, Medical Devices, Surgery, Clinical Trials, Other Health, Biotechnology, General Health, Health, Science, Other Science, Human, Low back pain, Sleep, Degenerative disc disease, Trial of the century, NB1, Patient, DDD, Bharat Immunologicals and Biologicals Corporation, Food, Safety, Pharmaceutical industry

Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committee (HREC) has approved Monash Health as the first of a planned multicenter pilot clinical trial to evaluate the Company’s NB1 bone graft in Australia.

Key Points: 
  • Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committee (HREC) has approved Monash Health as the first of a planned multicenter pilot clinical trial to evaluate the Company’s NB1 bone graft in Australia.
  • This pilot study will evaluate the safety and effectiveness of NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion (TLIF) to treat degenerative disc disease (DDD).
  • Inclusion criteria include patients with DDD at one level from L2-S1 who may also have up to Grade 1 spondylolisthesis or Grade 1 retrolisthesis at the involved level.
  • Bone Biologics previously announced the engagement of Avania as the contract research organization for this pilot clinical trial with NB1.

Aetna® Updates Disc Replacement Guidelines; All Major Payors Now Cover Centinel Spine's Lumbar Total Disc Replacement

Retrieved on: 
Thursday, March 2, 2023
FDA, Surgeon, Patient, TDR, News, WEST, DDD, Inter-satellite service, Samuel Bryan, Health insurance, Nursing, MD

Centinel Spine's prodisc® L remains the only FDA-approved TDR system for both one- and two-level use in the lumbar spine.

Key Points: 
  • Centinel Spine's prodisc® L remains the only FDA-approved TDR system for both one- and two-level use in the lumbar spine.
  • The new positive coverage policy opens access to patients suffering from one-level symptomatic degenerative disc disease (DDD) who may benefit from total disc replacement using a technology such as prodisc L. With Aetna's coverage update, all major commercial payors now cover one-level lumbar TDR.
  • "This announcement reaffirms the strong clinical and radiographic outcomes found in patients implanted with lumbar total disc replacements," stated Jack Zigler, MD, Texas Back Institute.
  • In addition to expanded one-level lumbar TDR coverage, patient access and treatment with the prodisc L Lumbar TDR system continues to advance in additional areas.